These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23723704)

  • 1. Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose.
    Samtani MN; Nuamah I; Gopal S; Remmerie B; Kern Sliwa J; Alphs L
    Neuropsychiatr Dis Treat; 2013; 9():721-30. PubMed ID: 23723704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.
    Samtani MN; Gopal S; Gassmann-Mayer C; Alphs L; Palumbo JM
    CNS Drugs; 2011 Oct; 25(10):829-45. PubMed ID: 21936586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
    Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
    Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
    Coppola D; Liu Y; Gopal S; Remmerie B; Samtani MN; Hough DW; Nuamah I; Sulaiman A; Pandina G
    BMC Psychiatry; 2012 Mar; 12():26. PubMed ID: 22455454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
    Fu DJ; Bossie CA; Sliwa JK; Ma YW; Alphs L
    Int Clin Psychopharmacol; 2014 Jan; 29(1):45-55. PubMed ID: 24113628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
    Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L
    BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data.
    Magnusson MO; Samtani MN; Plan EL; Jonsson EN; Rossenu S; Vermeulen A; Russu A
    CNS Drugs; 2017 Apr; 31(4):273-288. PubMed ID: 28258365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
    Gopal S; Vermeulen A; Nandy P; Ravenstijn P; Nuamah I; Buron Vidal JA; Berwaerts J; Savitz A; Hough D; Samtani MN
    Curr Med Res Opin; 2015 Nov; 31(11):2043-54. PubMed ID: 26306819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.
    Schreiner A; Bergmans P; Cherubin P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Hargarter L
    Clin Ther; 2014 Oct; 36(10):1372-88.e1. PubMed ID: 25444566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial.
    Bossie CA; Fu DJ; Sliwa JK; Ma YW; Alphs L
    Ther Adv Psychopharmacol; 2011 Aug; 1(4):111-24. PubMed ID: 23983935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.
    Pandina GJ; Lindenmayer JP; Lull J; Lim P; Gopal S; Herben V; Kusumakar V; Yuen E; Palumbo J
    J Clin Psychopharmacol; 2010 Jun; 30(3):235-44. PubMed ID: 20473057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.
    Carter NJ
    Drugs; 2012 May; 72(8):1137-60. PubMed ID: 22571444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension.
    Procyshyn RM; Lamoure JW; Katzman MA; Skinner PL; Sherman SE
    J Pharm Pharm Sci; 2019; 22(1):548-566. PubMed ID: 31730504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of paliperidone palmitate.
    Chue P; Chue J
    Expert Rev Neurother; 2012 Dec; 12(12):1383-97. PubMed ID: 23237346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review.
    González-Rodríguez A; Catalán R; Penadés R; Garcia-Rizo C; Bioque M; Parellada E; Bernardo M
    Patient Prefer Adherence; 2015; 9():695-706. PubMed ID: 26082620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.
    Pandina G; Lane R; Gopal S; Gassmann-Mayer C; Hough D; Remmerie B; Simpson G
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):218-26. PubMed ID: 21092748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia.
    Gopal S; Pandina G; Lane R; Nuamah I; Remmerie B; Coppola D; Hough D
    Innov Clin Neurosci; 2011 Aug; 8(8):26-33. PubMed ID: 21922067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia.
    Cleton A; Rossenu S; Crauwels H; Berwaerts J; Hough D; Gopal S; Eerdekens M; Vandebosch A; Remmerie B; De Meulder M; Rosso CM
    J Clin Pharmacol; 2014 Sep; 54(9):1048-57. PubMed ID: 24676998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.
    Kramer M; Litman R; Hough D; Lane R; Lim P; Liu Y; Eerdekens M
    Int J Neuropsychopharmacol; 2010 Jun; 13(5):635-47. PubMed ID: 19941696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.